BioFluidica has developed next generation disease diagnostic platforms. Diagnostic tests include capture and analysis of viable Circulating Tumor Cells, cell free DNA, and exosomes with unprecedented recovery, enabling disease diagnostics from a blood/liquid biopsy. The platform has been clinically validated on 6 cancer types and stroke. The commercial strategy includes a fee for service model as well as instrument and consumable offerings.